What's Happening?
A recent report from the Centers for Disease Control and Prevention (CDC) indicates that approximately 44% of U.S. adults using GLP-1 medications, such as Wegovy and Zepbound, have modified their prescribed usage. The most common alteration reported was
skipping doses, cited by 28% of users. The primary reasons for these changes were the high cost of the medications (38%) and issues with drug availability (36%). Younger adults, specifically those aged 18 to 39, were significantly more likely to cite cost as a factor, with 58% in this age group reporting it, compared to 20% of users aged 65 and older. The CDC's Rapid Surveys System collected data from 8,118 U.S. adults in July and August 2025, revealing that 9.8% had used a GLP-1 medication in the past year. The report also noted that 22.6% of GLP-1 users reported taking a compounded version of the drug, and these individuals were more likely to modify their usage.
Why It's Important?
This CDC report highlights a critical public health issue concerning medication adherence and access to GLP-1 drugs, which are vital for managing conditions like diabetes, obesity, and cardiovascular disease. When nearly half of users deviate from their prescribed regimen, it raises significant concerns about the drugs' effectiveness and patient safety, as the impact of such modifications on health outcomes has not been thoroughly studied. The disparity in cost impact between younger and older adults suggests inequities in healthcare coverage, with younger individuals often relying on employer plans that may limit weight-loss drug coverage or requiring them to pay out-of-pocket. This situation could lead to suboptimal disease management, potential health complications, and increased healthcare costs in the long run. Furthermore, the prevalence of compounded GLP-1 use and the higher rate of modification among these users introduce additional safety concerns, as compounded drugs are not FDA-reviewed and can vary in quality and dosing.
What's Next?
The CDC's findings underscore the urgent need for strategies to address the cost and accessibility barriers to GLP-1 medications. Healthcare providers are encouraged to discuss these challenges with their patients and explore options such as adjusting treatment plans, switching to covered drugs, or assisting with prior authorizations and appeals. Patients struggling with affordability are advised to consult their prescribers before altering their dosage, as restarting at a full dose after a break can increase side effects. Pharmacists can also play a role by informing patients about manufacturer savings programs or lower-cost direct purchase options. For Medicare beneficiaries, programs like the temporary Medicare GLP-1 Bridge program may offer some relief. Future data will be crucial to determine if recent price changes and Medicare programs effectively narrow the gap between prescribed use and real-world adherence. The report also implicitly calls for policymakers and pharmaceutical companies to re-evaluate pricing and coverage models to ensure equitable access to these important medications.
Beyond the Headlines
The widespread modification of GLP-1 drug regimens due to cost and access issues points to deeper systemic problems within the U.S. healthcare system. It highlights the tension between pharmaceutical innovation and affordability, where life-changing medications remain out of reach for many. This situation can exacerbate health disparities, as individuals with fewer financial resources may be unable to adhere to effective treatments, leading to poorer health outcomes. The rise in compounded drug use, while offering a cheaper alternative, introduces regulatory and safety concerns, creating a parallel market that operates with less oversight. Ethically, the issue raises questions about the right to access essential medicines and the responsibility of stakeholders—including drug manufacturers, insurers, and government—to ensure that effective treatments are both available and affordable. This trend could also influence future drug development, potentially pushing for more cost-effective formulations or alternative delivery methods to improve patient adherence and public health.













